173 related articles for article (PubMed ID: 17979482)
21. Hepatocellular carcinoma: A clinicopathological and immunohistochemical study of 116 cases from a tertiary care hospital in Southern India.
Hui M; Uppin SG; Uppin MS; Madhav TV; Varma GSR; Paul TR; Bheerappa N
Indian J Cancer; 2023; 60(2):191-198. PubMed ID: 37530240
[TBL] [Abstract][Full Text] [Related]
22. Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.
Pour AM; Masir N; Rose IM
Malays J Pathol; 2016 Dec; 38(3):229-233. PubMed ID: 28028292
[TBL] [Abstract][Full Text] [Related]
23. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.
Leong AS; Sormunen RT; Tsui WM; Liew CT
Histopathology; 1998 Oct; 33(4):318-24. PubMed ID: 9822920
[TBL] [Abstract][Full Text] [Related]
24. Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies?
de Boer WB; Segal A; Frost FA; Sterrett GF
Cancer; 2000 Oct; 90(5):273-8. PubMed ID: 11038423
[TBL] [Abstract][Full Text] [Related]
25. Fine needle aspiration diagnosis of hepatocellular carcinoma in metastatic sites.
Dusenbery D; Carr BI
Acta Cytol; 1996; 40(3):443-9. PubMed ID: 8669176
[TBL] [Abstract][Full Text] [Related]
26. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.
Al-Muhannadi N; Ansari N; Brahmi U; Satir AA
Ann Hepatol; 2011; 10(4):508-15. PubMed ID: 21911893
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic utility of CD10 immunohistochemical staining on cellblock in differentiating hepatocellular carcinoma from secondary malignancies of liver.
Singha J; Khan K; Chatterjee S
Indian J Pathol Microbiol; 2018; 61(4):510-515. PubMed ID: 30303139
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver.
Lin F; Abdallah H; Meschter S
Diagn Cytopathol; 2004 Feb; 30(2):92-7. PubMed ID: 14755758
[TBL] [Abstract][Full Text] [Related]
29. Loss of 5-hydroxymethylcytosine immunohistochemical expression is a useful diagnostic aid for distinguishing hepatocellular carcinoma in cytology fine needle aspiration specimens.
Zhu X; Dresser K; Chen BJ
Cytopathology; 2019 Sep; 30(5):492-498. PubMed ID: 31081979
[TBL] [Abstract][Full Text] [Related]
30. Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver.
Gokden M; Shinde A
Diagn Cytopathol; 2005 Sep; 33(3):166-72. PubMed ID: 16078249
[TBL] [Abstract][Full Text] [Related]
31. The use of immunohistochemistry in liver tumors.
Chan ES; Yeh MM
Clin Liver Dis; 2010 Nov; 14(4):687-703. PubMed ID: 21055690
[TBL] [Abstract][Full Text] [Related]
32. The Role of Immunocytochemical Markers to Differentiate Primary from Secondary Neoplastic Hepatic Masses: A Diagnostic Challenge on Cytology.
Bhattacharya JB; Jain SL; Devi S
Turk Patoloji Derg; 2021; 37(3):196-202. PubMed ID: 34514559
[TBL] [Abstract][Full Text] [Related]
33. Evaluating Liver Biopsies with Well-Differentiated Hepatocellular Lesions.
Umetsu SE; Kakar S
Surg Pathol Clin; 2023 Sep; 16(3):581-598. PubMed ID: 37536890
[TBL] [Abstract][Full Text] [Related]
34. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens.
Timek DT; Shi J; Liu H; Lin F
Am J Clin Pathol; 2012 Aug; 138(2):203-10. PubMed ID: 22904131
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of hepatocyte paraffin 1 antibody to discriminate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsies of the liver.
Zimmerman RL; Burke MA; Young NA; Solomides CC; Bibbo M
Cancer; 2001 Aug; 93(4):288-91. PubMed ID: 11507703
[TBL] [Abstract][Full Text] [Related]
36. Role of glypican-3 immunocytochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver utilizing fine needle aspiration cytology.
Zaakook M; Ayoub M; Sinna EA; El-Sheikh S
J Egypt Natl Canc Inst; 2013 Dec; 25(4):173-80. PubMed ID: 24207089
[TBL] [Abstract][Full Text] [Related]
37. Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver.
Ahuja A; Gupta N; Kalra N; Srinivasan R; Chawla Y; Rajwanshi A
Cytopathology; 2008 Aug; 19(4):229-35. PubMed ID: 18070122
[TBL] [Abstract][Full Text] [Related]
38. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
[TBL] [Abstract][Full Text] [Related]
39. Atypical Hepatocellular Neoplasms: Review of Clinical, Morphologic, Immunohistochemical, Molecular, and Cytogenetic Features.
Choi WT; Kakar S
Adv Anat Pathol; 2018 Jul; 25(4):254-262. PubMed ID: 29649004
[TBL] [Abstract][Full Text] [Related]
40. Immunohistological evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1.
Sugiki T; Yamamoto M; Aruga A; Takasaki K; Nakano M
J Surg Oncol; 2004 Nov; 88(2):104-7. PubMed ID: 15499598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
